Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 94
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT02384850 | Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor In Patients With Metastatic Colorectal Cancer | ||
| NCT05170789 | Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma | ||
| NCT07215832 | Karyopharm Expanded Access Program for Selinexor | ||
| NCT03095612 | Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC) | ||
| NCT07362225 | MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs) | ||
| NCT04768881 | Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma | ||
| NCT02228525 | Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes | ||
| NCT02138786 | Selinexor in Initial or Refractory and/or Relapsed Richter's Transformation | ||
| NCT03732703 | Myeloma-Developing Regimens Using Genomics (MyDRUG) | ||
| NCT02649790 | Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications | ||
| NCT02367690 | Study of Safety, Tolerability, and Pharmacokinetics of Topical Selinexor (KPT-330) Diabetic Foot Ulcer (DFU) Patients | ||
| NCT02213133 | Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas | ||
| NCT02403310 | A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML | ||
| NCT02303392 | Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma | ||
| NCT04607772 | Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) | ||
| NCT05177276 | Selinexor Combination Ph 1 Study | ||
| NCT04984330 | Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease | ||
| NCT03880123 | Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma | ||
| NCT02299518 | Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | ||
| NCT02078349 | Phase I Study of KPT330 in Asian Patients | ||
| NCT04661137 | A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma | ||
| NCT05028348 | A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma | ||
| NCT01607892 | Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer | ||
| NCT02471911 | KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma | ||
| NCT02120222 | Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery | ||
| NCT03466827 | Selinexor in Patients With Advanced Thymoma and Thymic Carcinoma | ||
| NCT01896505 | A Phase I Trial to Assess the Effects of Food and Formulation on PK of KPT-330 in Patients With Sarcoma | ||
| NCT02186834 | Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma | ||
| NCT02146833 | SHIP (Selinexor in Hormone Insensitive Prostate Cancer) | ||
| NCT02250885 | KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors | ||
| NCT01986348 | Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas | ||
| NCT04782687 | Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma | ||
| NCT02314247 | Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma | ||
| NCT02431351 | Efficacy & Safety Study of KPT-330 in Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndrome Patients | ||
| NCT02530476 | Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia | ||
| NCT05980806 | A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia | ||
| NCT02088541 | Selinexor (KPT-330) in Older Patients With Relapsed AML | ||
| NCT02536495 | Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer | ||
| NCT02436707 | Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma | ||
| NCT02091245 | Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML | ||
| NCT04355676 | Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Severe COVID-19 | ||
| NCT02780609 | Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma | ||
| NCT04349098 | Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection | ||
| NCT07200102 | Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma | ||
| NCT02628704 | Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma | ||
| NCT07447817 | Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias | ||
| NCT03955783 | Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies | ||
| NCT03191981 | Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple Myeloma | ||
| NCT05597345 | Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma | ||
| NCT02431364 | Trial of Safety and Tolerability of Oral Verdinexor (KPT-335) in Healthy Adults |
